Stock Track | Intellia Therapeutics Plummets 5.07% Intraday as ATM Offering Expansion Offsets FDA Clinical Hold Lift
Stock Track
Mar 02
Intellia Therapeutics' stock fell 5.07% during intraday trading on Monday, erasing earlier gains.
The decline followed the company's announcement that it has increased its at-the-market offering program to $1.04 billion, raising concerns about potential shareholder dilution.
This negative reaction overshadowed earlier positive news that the U.S. Food and Drug Administration had lifted a clinical hold on the company's MAGNITUDE Phase 3 trial for its gene therapy treatment nexiguran ziclumeran in transthyretin amyloidosis with cardiomyopathy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.